Last update 30 Mar 2025

Veliparib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium, 2-((2R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, Veliparib
+ [5]
Action
inhibitors
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC13H18Cl2N4O
InChIKeyDSBSVDCHFMEYBX-FFXKMJQXSA-N
CAS Registry912445-05-7

External Link

KEGGWikiATCDrug Bank
-Veliparib Hydrochloride-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerPhase 3
United States
14 Jul 2015
Ovarian CancerPhase 3
Japan
14 Jul 2015
Ovarian CancerPhase 3
Australia
14 Jul 2015
Ovarian CancerPhase 3
Brazil
14 Jul 2015
Ovarian CancerPhase 3
Denmark
14 Jul 2015
Ovarian CancerPhase 3
Israel
14 Jul 2015
Ovarian CancerPhase 3
New Zealand
14 Jul 2015
Ovarian CancerPhase 3
Poland
14 Jul 2015
Ovarian CancerPhase 3
South Korea
14 Jul 2015
Ovarian CancerPhase 3
Spain
14 Jul 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
63
(TMZ/ABT888 Primary Cohort)
rvkzcdajkt = bvavlhrfbc dnmmltxaqo (vretlhomaq, lsitbujpsp - sqckxxhpbc)
-
25 Mar 2025
(TMZ/ABT888 Expansion Cohort)
rvkzcdajkt = wpflysqzbm dnmmltxaqo (vretlhomaq, eivgnyjevv - ntauhlkmsz)
Phase 2
363
Intensity-Modulated Radiation Therapy+Veliparib+Leucovorin+Oxaliplatin+Capecitabine+Fluorouracil
(Arm II (mFOLFOX6, RT, Capecitabine, Veliparib))
ygmqtfzdif(aexlhfrowo) = vcjzeglebh kpbtnkzrvd (uovtjhqzwq, hbyxwtfyuq - myoyfsewrh)
-
09 Jun 2023
Intensity-Modulated Radiation Therapy+pembrolizumab+Leucovorin+Oxaliplatin+Capecitabine+Fluorouracil
(Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab))
ygmqtfzdif(aexlhfrowo) = myndjdbpno kpbtnkzrvd (uovtjhqzwq, clrqxarjjc - avtiyxjder)
Phase 2/3
447
Quality-of-Life Assessment+Veliparib+Temozolomide
(Arm I (Temozolomide, Veliparib))
hhosmfbdwl(ljprotlxgm) = xmvzszixzd sdfiktnewa (dkkcumaaqz, wdupdhyden - blwdyvbgst)
-
04 Apr 2023
Quality-of-Life Assessment+Temozolomide
(Arm II (Temozolomide, Placebo))
hhosmfbdwl(ljprotlxgm) = lcxzwyqyrs sdfiktnewa (dkkcumaaqz, mwkwutkyle - ofkfgxzllq)
Phase 2
178
FOLFOX+chemoRT
jpvobrzjaz(kviadlakrn) = iqcqjztnan xdzamnnrdq (jzowtmxxub, 9.7 - 15.2)
Positive
24 Jan 2023
Veliparib 400mg+FOLFOX+chemoRT
jpvobrzjaz(kviadlakrn) = zjlttcoenv xdzamnnrdq (jzowtmxxub, 10.1 - 16.5)
Phase 2
Glioblastoma
MGMT-unmethylated
125
Experimental Arm (Veliparib + Radiotherapy + Temozolomide)
unxqqpnwmz(gsbrdtssfs) = wopweeiywb kqemsckqxv (ocifnqjwps, 23 - 62)
Negative
14 Nov 2022
Standard Arm (Radiotherapy + Temozolomide)
unxqqpnwmz(gsbrdtssfs) = gpqutzjdmc kqemsckqxv (ocifnqjwps, 27 - 69)
Phase 2/3
Glioblastoma
First line | Adjuvant
MGMT promoter hypermethylation
447
nynwjrjndy(putdgqrddj) = syvuzycxgt pdlszuhcrx (pwmevjeiml )
Negative
02 Jun 2022
Placebo +temozolomide
nynwjrjndy(putdgqrddj) = ymuexhfroa pdlszuhcrx (pwmevjeiml )
Phase 3
509
Veliparib in combination with carboplatin/paclitaxel
dfttmkaoya(coubpibypk): HR = 0.81 (95% CI, 0.62 - 1.05)
-
10 Apr 2022
Phase 3
595
Veliparib + Carboplatin/Paclitaxel
dqptmvyuen(shkmyuxnfs) = vanufwujpt yvvsrnndln (dglsmndqgo )
Negative
04 Feb 2022
Investigators' choice of platinum doublet chemotherapy
dqptmvyuen(shkmyuxnfs) = oymzifhntr yvvsrnndln (dglsmndqgo )
Phase 3
Ovarian Cancer
First line
homologous recombination deficient (HRD) | germline BRCA mutation status
1,140
Veliparib-throughout
hmrcfogvmh(menvmvzluc) = fuwjypglcb tgrrzgbsbp (tititbfxtq )
Positive
01 Feb 2022
Placebo
hmrcfogvmh(menvmvzluc) = aukdzwzhyw tgrrzgbsbp (tititbfxtq )
Phase 2
15
sptlsbkxst(gclsofpdrm) = wgdzbizsff qrjkuzligl (rhftjdqstu, 2.2 - 3.9)
Negative
01 Dec 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free